Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes

被引:47
作者
Lee, KH
Lee, JH
Choi, SJ
Lee, JH
Kim, S
Seol, M
Lee, YS
Kim, WK
Lee, JS
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Sect Hematol, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Sect Oncol, Seoul 138736, South Korea
关键词
allogeneic hematopoietic cell transplantation-bone marrow reconstitution; trilineage reconstitution failure;
D O I
10.1038/sj.bmt.1704428
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The outcomes of patients who experience the failure to reconstitute a trilineage of blood cells after initial neutrophil engraftment were evaluated in 178 patients with hematologic disorders, who underwent allogeneic HCT. Of 165 qualified patients (five with primary engraftment failure; eight deaths before day 60 of HCT), 43 ( 26%) satisfied the criteria for the initial ( n = 22; failure of platelet > 20 000/mul or red blood cell transfusion independence/reticulocyte count greater than or equal to 1.0% by day 60) or subsequent ( n = 21, ANC < 500/μl for ≥ 3 days, platelet < 20 000/mul for greater than or equal to 7 days, or red blood cells transfusion/ reticulocyte < 1.0% after initial trilineage reconstitution) failure. GVHD was the most common clinical condition associated with cytopenia ( n = 24). In all, 20 patients ( 47%) recovered at least partially with a median of 52 days ( range 8 - 323) later, with 12 of those 20 patients recovering completely. The eventual reconstitution failure rate was 14% ( 23/ 163 patients). The number of cell lineages involved in the cytopenia was the only independent variable that predicted partial recovery ( 1 lineage vs 2 - 3 lineages with odds ratio of 8.69 ( 95% CI 1.96 - 38.60), P = 0.004). Five/ 20 patients with vs 20/ 23 patients without partial recovery died. Trilineage reconstitution failures after allogeneic HCT need systematic analysis in the future studies.
引用
收藏
页码:729 / 734
页数:6
相关论文
共 19 条
[1]   BONE-MARROW TRANSPLANTATION (BMT) VERSUS IMMUNOSUPPRESSION FOR THE TREATMENT OF SEVERE APLASTIC-ANEMIA (SAA) - A REPORT OF THE EBMT SAA WORKING PARTY [J].
BACIGALUPO, A ;
HOWS, J ;
GLUCKMAN, E ;
NISSEN, C ;
MARSH, J ;
VANLINT, MT ;
CONGIU, M ;
DEPLANQUE, MM ;
ERNST, P ;
MCCANN, S ;
RAGAVASHAR, A ;
FRICKHOFEN, N ;
WURSCH, A ;
MARMONT, AM ;
GORDONSMITH, EC .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (02) :177-182
[2]  
CHAMPLIN RE, 1989, BLOOD, V73, P606
[3]  
DEEG HJ, 1984, ANNU REV MED, V35, P11, DOI 10.1146/annurev.med.35.1.11
[4]   Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection [J].
Dubovsky, J ;
Daxberger, H ;
Fritsch, G ;
Printz, D ;
Peters, C ;
Matthes, S ;
Gadner, H ;
Lion, T .
LEUKEMIA, 1999, 13 (12) :2060-2069
[5]   Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine [J].
Frickhofen, N ;
Rosenfeld, SJ .
SEMINARS IN HEMATOLOGY, 2000, 37 (01) :56-68
[6]   Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation [J].
Grandage, VL ;
Cornish, JM ;
Pamphilon, DH ;
Potter, MN ;
Steward, CG ;
Oakhill, A ;
Marks, DI .
BONE MARROW TRANSPLANTATION, 1998, 21 (07) :687-690
[7]   The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation [J].
Ho, VT ;
Soiffer, RJ .
BLOOD, 2001, 98 (12) :3192-3204
[8]   Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study [J].
Lee, JH ;
Lee, KH ;
Kim, S ;
Lee, JS ;
Kim, WK ;
Park, CJ ;
Chi, HS ;
Kim, SH .
BONE MARROW TRANSPLANTATION, 1998, 22 (09) :883-888
[9]   Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation [J].
Lee, JH ;
Lee, JH ;
Choi, SJ ;
Kim, S ;
Seol, M ;
Kwon, SW ;
Park, CJ ;
Chi, HS ;
Lee, JS ;
Kim, WK ;
Lee, KH .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (04) :702-710
[10]   Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide [J].
Lee, JH ;
Lee, KH ;
Lee, JH ;
Kim, S ;
Seol, M ;
Park, CJ ;
Chi, HS ;
Kang, W ;
Kim, ST ;
Kim, WK ;
Lee, JS .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) :1087-1094